WallStSmart

HealthStream Inc (HSTM)vs10X Genomics Inc (TXG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

10X Genomics Inc generates 99% more annual revenue ($638.78M vs $321.12M). HSTM leads profitability with a 6.6% profit margin vs -3.5%. HSTM earns a higher WallStSmart Score of 51/100 (C-).

HSTM

Buy

51

out of 100

Grade: C-

Growth: 6.0Profit: 5.0Value: 3.7Quality: 6.5
Piotroski: 3/9Altman Z: 2.33

TXG

Avoid

20

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 6.7Quality: 7.0
Piotroski: 3/9Altman Z: 1.02
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for HSTM.

TXGUndervalued (+68.1%)

Margin of Safety

+68.1%

Fair Value

$60.02

Current Price

$57.75

$2.27 discount

UndervaluedFair: $60.02Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HSTM3 strengths · Avg: 8.7/10
Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

EPS GrowthGrowth
28.4%8/10

Earnings expanding 28.4% YoY

TXG1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.1010/10

Conservative balance sheet, low leverage

Areas to Watch

HSTM4 concerns · Avg: 3.3/10
P/E RatioValuation
39.9x4/10

Premium valuation, high expectations priced in

Market CapQuality
$839.77M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
5.7%3/10

ROE of 5.7% — below average capital efficiency

Profit MarginProfitability
6.6%3/10

6.6% margin — thin

TXG4 concerns · Avg: 3.3/10
Price/BookValuation
9.2x4/10

Trading at 9.2x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-2.8%2/10

ROE of -2.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : HSTM

The strongest argument for HSTM centers on Debt/Equity, Price/Book, EPS Growth. Revenue growth of 12.5% demonstrates continued momentum.

Bull Case : TXG

The strongest argument for TXG centers on Debt/Equity.

Bear Case : HSTM

The primary concerns for HSTM are P/E Ratio, Market Cap, Return on Equity.

Bear Case : TXG

The primary concerns for TXG are Price/Book, EPS Growth, Piotroski F-Score.

Key Dynamics to Monitor

HSTM profiles as a value stock while TXG is a turnaround play — different risk/reward profiles.

TXG carries more volatility with a beta of 2.04 — expect wider price swings.

HSTM is growing revenue faster at 12.5% — sustainability is the question.

TXG generates stronger free cash flow (25M), providing more financial flexibility.

Bottom Line

HSTM scores higher overall (51/100 vs 20/100) and 12.5% revenue growth. TXG offers better value entry with a 68.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

HealthStream Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

HealthStream, Inc. provides provider and staff solutions for healthcare organizations in the United States. The company is headquartered in Nashville, Tennessee.

Visit Website →

10X Genomics Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and Asia Pacific. The company is headquartered in Pleasanton, California.

Want to dig deeper into these stocks?